logo.jpg
Anti TIGIT Therapies Market Insight 2023
26 juin 2023 07h12 HE | KuicK Research
Delhi, June 26, 2023 (GLOBE NEWSWIRE) -- Global Anti TIGIT Antibody Clinical Trials and Companies Insight 2023 Report Highlights: Global Anti TIGIT Antibodies Market DynamicsInsight On Anti...
Coherus BioSciences, Inc. logo
Coherus and Junshi Biosciences Expand Immuno-Oncology Collaboration to Include TIGIT-Targeted Antibody
10 janv. 2022 07h30 HE | Coherus BioSciences, Inc.
•  Coherus and Junshi Biosciences plan to evaluate the toripalimab + JS006 combinationin clinical trials in multiple tumor types •  Combinations of PD-1 + TIGIT inhibitors have potential to expand...
Cascadian Therapeuti
Cascadian Therapeutics Highlights Preclinical Program Presentations at the American Association for Cancer Research Annual Meeting 2017
05 avr. 2017 08h00 HE | Cascadian Therapeutics, Inc.
SEATTLE, April 05, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced data highlights from presentations of preclinical...
OncoMed Pharmaceuticals, Inc. Logo
OncoMed Pharmaceuticals Announces Fourth Quarter and Full Year 2016 Financial Results
08 mars 2017 16h05 HE | OncoMed Pharmaceuticals, Inc.
Demcizumab and Tarextumab Randomized Phase 2 Data Expected 1H 2017 Anti-TIGIT IND Accepted; GITRL-Fc IND Expected 1H 2017 OncoMed Management to Host Conference Call/Webcast this Afternoon at 4:30...
OncoMed Pharmaceuticals, Inc. Logo
OncoMed Announces Multiple Abstracts Related to Anti-TIGIT Program Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2017
02 mars 2017 08h30 HE | OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., March 02, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) will present new data related to its clinical and preclinical immuno-oncology and anti-cancer stem...
OncoMed Pharmaceuticals, Inc. Logo
OncoMed Announces Year-End Cash Balance and 2017 Outlook
05 janv. 2017 08h30 HE | OncoMed Pharmaceuticals, Inc.
Enters 2017 with $184.6 Million in Cash Potential for Five Program Opt-ins Totaling Over $170M Anti-TIGIT (I/O#2) IND Filed REDWOOD CITY, Calif., Jan. 05, 2017 (GLOBE NEWSWIRE) -- OncoMed...